Candel Therapeutics, Inc. (CADL) vs Lexicon Pharmaceuticals, Inc. (LXRX)
A side-by-side comparison of Candel Therapeutics, Inc. and Lexicon Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CADL
Candel Therapeutics, Inc.
$10.15HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT
LXRX
Lexicon Pharmaceuticals, Inc.
$1.72HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT
Total return — CADL vs LXRX
growth of $100 · dividends reinvested · last 5yCADL +46.1% (+7.9%/yr)LXRX -51.0% (-13.3%/yr)CADL compounded faster over this window
CADL LXRX
CADL vs LXRX: by the numbers
- •LXRX is the larger company ($764M vs $744M market cap).
- •Both run net losses; CADL's is the smaller (0.00% vs -147.38% net margin).
Metrics side by side
Valuation
| Metric | CADL | LXRX |
|---|---|---|
| P/S ratio | N/A | 18.42 |
| P/B ratio | 5.90 | 4.38 |
Profitability
| Metric | CADL | LXRX |
|---|---|---|
| Gross margin | 0.00% | 98.85% |
| Operating margin | 0.00% | -98.21% |
| Net margin | 0.00% | -147.38% |
| ROE | -70.19% | -35.02% |
| ROIC | -36.83% | -23.16% |
Growth (annualized)
| Metric | CADL | LXRX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 42.36% |
| Total return CAGR (5Y) | -1.42% | -18.54% |
Frequently asked
- How have CADL and LXRX total returns compared?
- Over the past 5 years, CADL delivered -1.42% and LXRX delivered -18.54% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Candel Therapeutics ROELexicon Pharmaceuticals ROECandel Therapeutics operating marginLexicon Pharmaceuticals operating marginCandel Therapeutics revenue growthLexicon Pharmaceuticals revenue growthCandel Therapeutics free cash flowLexicon Pharmaceuticals free cash flow
Candel Therapeutics & Lexicon Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.